Allarity Therapeutics announced that on October 9, 2024, it received a formal notice from The Nasdaq Stock Market, LLC’s Office of General Counsel. The notice confirmed that the Company has regained compliance with the minimum bid price requirement as set forth in Nasdaq’s Listing Rule 5550(a)(2). Nasdaq noted that since September 11, 2024, Allarity’s stock has maintained a closing bid price of $1.00 or more for 20 consecutive trading days, thereby meeting the requirements for regaining compliance with the Bid Price Rule.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLR:
- ALLR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Allarity names Jeremy Graff as president, CDO, Jose Iglesias as consultant CMO
- Allarity Therapeutics Strengthens Leadership for Cancer Programs
- Allarity Therapeutics Nears Regulatory Approval with Stenoparib Trial Success
- Allarity announces two patients exceeding one year treatment with stenoparib
Questions or Comments about the article? Write to editor@tipranks.com